MADRID, Nov. 11, 2021 /PRNewswire/ -- PharmaMar S.A.
(MSE: PHM) has announced today a licensing agreement with Lotus
Pharmaceutical CO., LTD. (TWSE:1795) to commercialize the
anticancer drug lurbinectedin in Taiwan.
Under the terms of the license and commercialization agreement,
PharmaMar will receive a non-disclosed upfront payment and will be
eligible for additional remunerations, including regulatory and
sales milestone payments. PharmaMar will retain production rights
and will sell the product to Lotus for its clinical and commercial
use.
Lotus will pursue the marketing approval in Taiwan and have the right to market the
product exclusively upon approval.
Lurbinectedin was granted accelerated approval by FDA (Food and
Drug Administration) for the treatment of metastatic Small Cell
Lung Cancer in 2020. In addition, in 2021, lurbinectedin has
received marketing approval in the United
Arab Emirates, Canada,
Australia and Singapore.
According to Luis Mora,
General Manager of PharmaMar's Oncology and Virology Business
Units, "We are very pleased to sign this new agreement with
Lotus, which will allow, if approved, to bring lurbinectedin to all
appropriate patients in Taiwan."
Petar Vazharov, Chief Executive Officer of Lotus, said:
"Lung cancer has been among the top cause of death in
Taiwan for decades. We are very
honored to have this opportunity partnering with PharmaMar to offer
the patients in Taiwan access to
innovative drug, which is aligned with our key focused therapeutic
area."
Media Contact:
Miguel Martínez-Cava – Communication
Manager
mmartinez-cava@pharmamar.com
Mobile: +34 606597464
Phone: +34 918466000
Capital Markets & Investor Relations:
José Luis
Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor
Relations
investorrelations@pharmamar.com
Phone: +34 914444500
Or please visit our website at www.pharmamar.com